Gubra:Data virker bedre end styrtdykkende aktie tilsiger
-
Kommentar fra Per Hansen, Investeringsøkonom, Nordnet
Gubra har offentliggjort fase 1 data fra ABBV-295
Fase 1 er 5-6 år væk fra markedet, i givet fald
Vægttab på 7,75-9,79 % er fornuftigt
Ikke mindst fordi det i hovedsagen er mænd, som der er testet på, og erfaringer viser at kvinder taber sig mere
Der er samtidig testet på BMI under 30.Aktien sendes massivt ned, men data er ikke så dårlige som aktiekursen i dag udtrykker
-
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
AbbVie (NYSE: ABBV) today announced positive topline results1 from the multiple ascending dose (MAD) part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of subcutaneous ABBV-295, in adults with a mean body mass index (BMI) of less than 30 kg/m2. ABBV-295 is a long-acting amylin analog that represents a mechanistically distinct class from incretin-based therapies such as GLP-1 and GIP receptor agonists.
Yahoo Finance (finance.yahoo.com)
-
AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
https://news.abbvie.com/2026-03-09-AbbVie-Announces-Positive-Topline-Results-from-a-Phase-1-Multiple-Ascending-Dose-Study-of-ABBV-295,-a-Long-Acting-Amylin-Analog,-in-Adults"Study enrollment mostly comprised male participants (88.3%)."
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
https://clinicaltrials.gov/study/NCT06144684
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
https://clinicaltrials.gov/study/NCT07291232A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
https://clinicaltrials.gov/study/NCT07414784
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind